U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk ...
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results